Regeneron does not undertake any obligation ... which has already achieved over 40% enrollment. Our CD28 co-stimulatory bispecifics for solid tumors are also progressing. We're working to mitigate ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. My name is Tawanda, and I will be your ...